Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Pinato

Showing results (31-40 of 286) with videos related to

Pageof 29
Sort By:
Hepatology (Baltimore, Md.)|December 26, 2024
Reply: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatmentCiro Celsa, Giuseppe Cabibbo, David J Pinato
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2014
An unexpected cause of pulmonary cannonball lesionDavid J Pinato, Wallace Tan, Amy Gately
Human Vaccines & Immunotherapeutics|June 24, 2020
Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?Nadiya Hussain, Muntaha Naeem, David J Pinato
JAMA Oncology|February 21, 2020
Antibiotic Treatment and Immune Checkpoint Inhibitor Therapy in Patients With Cancer-ReplyDavid J Pinato, Thomas Newsom-Davis, Mark Bower
Liver International : Official Journal of the International Association for the Study of the Liver|August 22, 2019
The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinomaChandan Sanghera, Jhia J Teh, David J Pinato
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2021
Back from the Brink: EGFR Inhibition in Gastroesophageal CancerMark R Openshaw, David J Pinato, Nicola Valeri
European Journal of Cancer (Oxford, England : 1990)|August 16, 2021
Response to letter entitled: Re: Predictive ability of a drug-based score in advanced non-small cell lung cancer patients receiving first-line immunotherapyAlessio Cortellini, Melissa Bersanelli, David J Pinato, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|November 20, 2019
Acceleration of interstitial lung disease induced by raltitrexedSarah Howlett, Raminder Aul, Mark Hill, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 27, 2022
Antibiotic Exposure and Immune Checkpoint Inhibitors in Patients With NSCLC: The Backbone MattersAlessio Cortellini, Francesco Facchinetti, Lisa Derosa, et al.
Nature Medicine|February 27, 2024
Immunotherapy at all stages of hepatocellular carcinomaDavid J Pinato, Claudia A M Fulgenzi, Antonio D'Alessio
Pageof 29

Showing results (31-40 of 286) with videos related to

Sort By:
Pageof 29
Hepatology (Baltimore, Md.)|December 26, 2024
Reply: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatmentCiro Celsa, Giuseppe Cabibbo, David J Pinato
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2014
An unexpected cause of pulmonary cannonball lesionDavid J Pinato, Wallace Tan, Amy Gately
Human Vaccines & Immunotherapeutics|June 24, 2020
Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?Nadiya Hussain, Muntaha Naeem, David J Pinato
JAMA Oncology|February 21, 2020
Antibiotic Treatment and Immune Checkpoint Inhibitor Therapy in Patients With Cancer-ReplyDavid J Pinato, Thomas Newsom-Davis, Mark Bower
Liver International : Official Journal of the International Association for the Study of the Liver|August 22, 2019
The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinomaChandan Sanghera, Jhia J Teh, David J Pinato
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2021
Back from the Brink: EGFR Inhibition in Gastroesophageal CancerMark R Openshaw, David J Pinato, Nicola Valeri
European Journal of Cancer (Oxford, England : 1990)|August 16, 2021
Response to letter entitled: Re: Predictive ability of a drug-based score in advanced non-small cell lung cancer patients receiving first-line immunotherapyAlessio Cortellini, Melissa Bersanelli, David J Pinato, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|November 20, 2019
Acceleration of interstitial lung disease induced by raltitrexedSarah Howlett, Raminder Aul, Mark Hill, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 27, 2022
Antibiotic Exposure and Immune Checkpoint Inhibitors in Patients With NSCLC: The Backbone MattersAlessio Cortellini, Francesco Facchinetti, Lisa Derosa, et al.
Nature Medicine|February 27, 2024
Immunotherapy at all stages of hepatocellular carcinomaDavid J Pinato, Claudia A M Fulgenzi, Antonio D'Alessio
Pageof 29